| Name | norethisterone acetate |
|---|---|
| Synonyms |
NORLUTATE
17beta-Hydroxy-19-norpregn-4-en-20-yn-3-one acetate 19-NORETHISTERONE 17-ACETATE NORETHISTERONE ACETATE 17-beta-acetoxy-19-nor-17-alpha-pregn-4-en-20-yn-3-one 4-ESTREN-17ALPHA-ETHYNYL-17BETA-OL-3-ONE 17-ACETATE 17-HYDROXY-19-NOR-17ALPHA-4-PREGNEN-20-YN-3-ONE ACETATE 17-Hydroxy-19-nor-17alpha-pregn-4-en-20-yn-3-one acetate 17β-Acetoxy-19-nor-17α-pregn-4-en-20-yn-3-one 17-alpha-ethinyl-19-nortestosteroneacetate (17α)-3-Oxo-19-norpregn-4-en-20-yn-17-yl acetate 17α-Ethinyl-19-nortestosterone-17β-acetate MFCD04039850 17-alpha-ethynyl-17-beta-acetoxy-19-norandrost-4-en-3-one NORETHISTERONE ACETATE, IMP. G : 6-KETONORETHISTERONE ACETATE, MM(CRM STANDD) SH-420C [(8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate 17-Ent 17-Acetoxy-19-nor-17α-pregn-4-en-20-yn-3-one Norethindrone acetate 17-hydroxy-19-nor-17-alpha-pregn-4-en-20-yn-3-oneacetate 17-acetoxy-19-nor-17-alpha-pregn-4-en-20-yn-3-on 17-Acetoxy-19-nor-17alpha-pregn-4-en-20-yn-3-one 17-Hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one acetate EINECS 200-132-0 17ALPHA-ETHYNYL-17BETA-HYDROXY-19-NOR-4-ANDROSTEN-3-ONE 17-ACETATE 17alpha-Ethinyl-19-nortestosterone acetate 17-α-Ethinyl-19-nortestosterone-17-β-acetate 19-NORETHISTERONE 17-ACETATE MIN. ( 17-Acetyloxy(17alpha)-19-norpregn-4-estren-17beta-ol-acetate-3-one 17α-Ethynyl-17-hydroxyestr-4-en-3-one acetate Norethindrone 17-acetate (17α)-17-(acetyloxy)-19-norpregn-4-en-20-yn-3-one 19-Nor-17α-ethynyltestosterone Acetate Estr-4-en-3-one, 17α-ethynyl-17-hydroxy-, acetate 17ALPHA-ETHYNYL-19-NORTESTOSTERONE 17BETA-ACETATE NORETHISTERONE ACETATE, IMP. B : 3-OXO-19-NOR-17ALPHA-PREGN-5(10-EN-20YN-17YL ACETATE MM(CRM STANDD) 19-NORETHISTERONE ACETATE 19-Nor-17α-pregn-4-en-20-yn-3-one, 17-hydroxy-, acetate (8CI) Norethisteron acetate NORETHISTERONE ACETATE, IMP. A : NORETHISTERONE MM(CRM STANDD) (17-alpha)-17-(Acetyloxy)-19-norpregn-4-en-20-yn-3-one 17α-Ethinyl-19-nortestosterone acetate 17α-Ethynyl-19-nortestosterone acetate ACETIC ACID 17-ETHYNYL-13-METHYL-3-OXO-2,3,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPE 17alpha-Ethinyl-19-nortestosterone 17beta-acetate NORETHISTERONE ACETATE, IMP. F : 6-HYDROXYNORETHISTERONE ACETATE, MM(CRM STANDD) NorethisteroneAcetateBp93 acetic acid (17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl) ester 17-hydroxy-19-nor-17a-4-pregnen-20-yn-3-one acetate 19-Nor-17α-pregn-4-en-20-yn-3-one, 17-hydroxy-, acetate 17alpha-Ethynyl-17beta-acetoxy-19-norandrost-4-en-3-one 17-Ethynyl-3-oxoestr-4-en-17-yl acetate NORETHISTERONE ACETATE, STANDD 17-α-Ethynyl-19-nortestosterone acetate 17ALPHA-ETHYNYL-19-NORTESTOSTERONE ACETATE Milligynon 17-alpha-ethynyl-17-hydroxyestr-4-en-3-oneacetate Norethisterone acetate for system suitability 17alpha-Ethynyl-17-hydroxyestr-4-en-3-one acetate 17α-Ethynyl-17β-acetoxy-19-norandrost-4-en-3-one 19-NOR-17ALPHA-ETHYNYLTESTOSTERONE ACETATE 19-NORESTHISTERONE ACETATE 17-alpha-ethinyl-19-nortestosterone-17-beta-acetate Norethisterone acetate NORETHINDRONE ACETATE CRYSTALLINE 17-Acetyloxy-17-ethinylestr-4-en-3-one Primolut-Nor 17-acetyloxy(17-alpha)-19-norpregn-4-estren-17-beta-ol-acetate-3-one 19-NORETHINDRONE ACETATE 17-acetoxy-19-nor-17-alpha-pregn-4-en-20-yn-3-one NORETHISTERONE ACETATE, MM(CRM STANDD) 17beta-Acetoxy-19-nor-17alpha-pregn-4-en-20-yn-3-one 4-ESTREN-17-ALPHA-ETHYNYL-17-BETA-OL-3-ONE ACETATE Norlutin A 17-beta-hydroxy-19-nor-17-alpha-pregn-4-en-20-yn-3-oneacetate Norlutin acetate 17β-Hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one acetate NORETHISTERONE ACETATE, WHO STANDD 17α-ethynyl-17β-hydroxy-19-nor-4-androsten-3-one 17-acetate NORETHINDRONE ACETATE Aygestin 17beta-Hydroxy-19-nor-17alpha-pregn-4-en-20-yn-3-one acetate (8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate Norlutin-A 17a-ethynyl-19-nortestosterone 17b-acetate |
| Description | Norethindrone acetate is a female progestin approved by FDA for the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels, and secondary amenorrhea. |
|---|---|
| Related Catalog | |
| Target |
Progesterone Receptor[1] |
| In Vivo | Norethindrone acetate could be a cost-effective alternative with relatively mild side effects in the treatment of symptomatic endometriosis. Subjects treated with norethindrone acetate obtain dysmenorrhea and noncyclic pelvic pain relief[1]. Norethindrone acetate alone is a well-tolerated, effective option to manage pain and bleeding for all stages of endometriosis. Post-Norethindrone acetate bleeding scores are improved regardless of prior hormonal regimen, and post-Norethindrone acetate pain scores improved in all patients except for those previously prescribed GnRH-agonist plus add-back[2]. Norethindrone acetate shows low acute toxicity in experimental animals and is consistent with the lack of toxicity seen in humans. Administration of norethindrone acetate alone to rodents at several multiples of the human dose results in no treatment related mortality, hematological changes, behavioral changes, or organ pathology[3]. Norethindrone acetate administration leads to significant and proportional reductions of the concentrations of triglycerides, cholesterol and phospholipids of plasma lipoproteins of density <1.006 of rats fed a high carbohydrate diet. Norethindrone acetate (0.1 mM) also significantly inhibits the incorporation of both palmitate and glycerol into triglycerides of isolated hepatocytes from fed rats[4]. |
| Animal Admin | Rats: Female Sprague-Dawley rats (200-210 g), 6 of which serve as controls, are individually caged in an animal room illuminated from 9:00 a.m. to 9:00 p.m. Each of the 7 rats receiving norethindrone acetate is fed 35 μg/day for 2 weeks. Water and the rat chow which is high in carbohydrate are available ad libitum[4]. |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 454.7±45.0 °C at 760 mmHg |
| Molecular Formula | C22H28O3 |
| Molecular Weight | 340.456 |
| Flash Point | 197.1±28.8 °C |
| Exact Mass | 340.203857 |
| PSA | 43.37000 |
| LogP | 3.99 |
| Vapour Pressure | 0.0±1.1 mmHg at 25°C |
| Index of Refraction | 1.556 |
| Storage condition | 2~8°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
| Symbol |
GHS08 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H351 |
| Precautionary Statements | P281 |
| Personal Protective Equipment | Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
| Hazard Codes | Xn:Harmful |
| Risk Phrases | R40;R48 |
| Safety Phrases | S36/37 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | RC8965000 |
| HS Code | 2915299090 |
|
~96%
51-98-9 |
| Literature: Leung; Karunanithy; Becket; Yeo Steroids, 1985 , vol. 46, # 1 p. 639 - 647 |
|
~87%
51-98-9 |
| Literature: Zhou, Dong; Carlson, Kathryn E.; Katzenellenbogen, John A.; Welch, Michael J. Journal of Medicinal Chemistry, 2006 , vol. 49, # 15 p. 4737 - 4744 |
|
~%
51-98-9 |
| Literature: Iriarte et al. Journal of the American Chemical Society, 1959 , vol. 81, p. 436 |
|
~%
51-98-9 |
| Literature: Iriarte et al. Journal of the American Chemical Society, 1959 , vol. 81, p. 436 |
| HS Code | 2915299090 |
|---|---|
| Summary | 2915299090 salts of acetic acid。supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward)。VAT:17.0%。tax rebate rate:9.0%。MFN tariff:5.5%。general tariff:50.0% |